Literature DB >> 31332071

A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.

Michaelle Chojnacki1, Alesa Philbrick1, Tyler Scherzi1, Nicole Pecora2, Paul M Dunman1, Rachel A F Wozniak3.   

Abstract

Bacterial keratitis causes significant blindness, yet antimicrobial resistance has rendered current treatments ineffective. Polymyxin B-trimethoprim (PT) plus rifampin has potent in vitro activity against Staphylococcus aureus and Pseudomonas aeruginosa, two important causes of keratitis. Here we further characterize this combination against P. aeruginosa in a murine keratitis model. PT plus rifampin performed comparably to or better than moxifloxacin, the gold standard, suggesting that the combination may be a promising therapy for bacterial keratitis.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  antimicrobial combinations; drug discovery; eye; keratitis

Mesh：

Substances：

Year:  2019        PMID： 31332071      PMCID： PMC6761539          DOI： 10.1128/AAC.00777-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Visual outcomes in treated bacterial keratitis: four years of prospective follow-up.

Authors:  Scott M McClintic; Namperumalsamy V Prajna; Muthiah Srinivasan; Jeena Mascarenhas; Prajna Lalitha; Revathi Rajaraman; Catherine E Oldenburg; Kieran S O'Brien; Kathryn J Ray; Nisha R Acharya; Thomas M Lietman; Jeremy D Keenan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-02       Impact factor: 4.799

Review 2.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

Review 3.  Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.

Authors:  Marguerite McDonald; Joseph M Blondeau
Journal:  J Cataract Refract Surg       Date:  2010-09       Impact factor: 3.351

4.  Balance of pro- and anti-inflammatory cytokines correlates with outcome of acute experimental Pseudomonas aeruginosa keratitis.

Authors:  A Thakur; M Xue; F Stapleton; A R Lloyd; D Wakefield; M D P Willcox
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

5.  A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.

Authors:  David B Granet; Mark Dorfman; David Stroman; Paul Cockrum
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2008 Nov-Dec       Impact factor: 1.402

Review 6.  Pathogenesis of Pseudomonas aeruginosa ocular diseases.

Authors:  A S Kreger
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

7.  Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.

Authors:  R Gleckman; N Blagg; D W Joubert
Journal:  Pharmacotherapy       Date:  1981 Jul-Aug       Impact factor: 4.705

8.  Dominant susceptibility effect on the murine corneal response to Pseudomonas aeruginosa.

Authors:  K W Beisel; L D Hazlett; R S Berk
Journal:  Proc Soc Exp Biol Med       Date:  1983-04

9.  Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Authors:  Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Durga S Borkar; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Ophthalmic Epidemiol       Date:  2013-05-10       Impact factor: 1.648

10.  Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.

Authors:  Penny A Asbell; Christine M Sanfilippo; Christopher M Pillar; Heleen H DeCory; Daniel F Sahm; Timothy W Morris
Journal:  JAMA Ophthalmol       Date:  2015-12       Impact factor: 7.389
View more
  2 in total

1.  Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.

Authors:  Jia A Mei; William Johnson; Bailey Kinn; Emily Laskey; Lydia Nolin; Pratham Bhamare; Charlotte Stalker; Paul M Dunman; Rachel A F Wozniak
Journal:  Transl Vis Sci Technol       Date:  2022-05-02       Impact factor: 3.048

2.  Efficacy of a Novel Ophthalmic Antimicrobial Drug Combination Toward a Large Panel of Staphylococcus aureus Clinical Ocular Isolates From Around the World.

Authors:  Emily Laskey; Yimin Chen; Michael B Sohn; Emma Gruber; Michaelle Chojnacki; Rachel A F Wozniak
Journal:  Cornea       Date:  2020-10       Impact factor: 3.152
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.